European approval of paediatric license extension of dupilumab (Dupixent) for severe atopic dermatitis
License extension is for treatment of severe atopic dermatitis in 6 to 11 year olds who are candidates for systemic therapy and is based on phase III data which demonstrated an 82% mean improvement in disease extent and severity when administered 4 weekly vs 49% for placebo.
Source:
PharmaTimes